What Pharma Gains from Structured RBM?

Interview with Artem Andrianov during PCT 2015:

What Pharma Gains from Structured RBM?

By | 2016-11-16T18:35:35+00:00 March 20, 2016|Blog|0 Comments

About the Author:

Professional in the integration of data-driven Risk-based Monitoring (RbM) process in international clinical trials of pharmacology. Speaker at regional and global conferences such as: DIA, PharmaForum, PharmaDay, DGGF, etc. 10+ years of experience in data quality projects and biostatistics for the pharmaceutical industry. Life passion: improving clinical research with RbM, driving the RbM research to new frontiers for CROs, pharma and biotech companies.

Leave A Comment

Register Today!

Get Free Test Access